Athira Pharma Inc (ATHA) Government Trades - Latest Congressional Stock Transactions
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
top performing (ATHA) trades
Recent Athira Pharma (ATHA) Trades by Congress Members
See the most up-to-date Athira Pharma trades disclosed by US lawmakers, including purchase and sale amounts, transaction dates, and reporting details. View the most recent Athira Pharma trades made by congress members.
Chris JacobsHouse (R-NY) | $1K - $15K | stock | Purchase | Dec 12, 2022 | House |
